Reducing Clinical Trial Burdens Brings Greater Participant Diversity – PhRMA
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.
You may also be interested in...
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
NCI networks had vast under accrual in the past year, but Sharpless says industry has been affected to a greater degree. He says the institute also has been better at accruing minority patients.
COVID-19 trials could have reached underserved populations better if research infrastructure was in place where people routinely get their health care, acting commissioner Janet Woodcock says; PhRMA is looking to establish a public-private partnership that would build a sustainable community-based infrastructure for clinical research.